Related Experiment Videos
High-dose intravenous gammaglobulin for Kawasaki disease
Insights
High-dose intravenous immunoglobulin (IVIG) significantly reduces coronary artery lesions in Kawasaki disease. This treatment, combined with aspirin, proved more effective than aspirin alone in preventing cardiac complications.
Area of Science:
- Pediatric Cardiology
- Immunology
- Rheumatology
Background:
- Kawasaki disease is a leading cause of acquired heart disease in children.
- Coronary artery lesions are a significant complication of Kawasaki disease.
- Aspirin is the conventional treatment, but its efficacy in preventing coronary artery lesions is limited.
Purpose of the Study:
- To evaluate the efficacy of high-dose intravenous immunoglobulin (IVIG) plus aspirin in preventing coronary artery lesions in Kawasaki disease.
- To compare IVIG plus aspirin with aspirin alone in a multicenter controlled trial.
Main Methods:
- A randomized controlled trial involving 85 patients with Kawasaki disease.
- Patients were assigned to receive either aspirin alone or IVIG plus aspirin.
- Coronary artery dilatation was monitored using two-dimensional echocardiography and confirmed with coronary arteriography when necessary.
Main Results:
- Within 29 days, coronary artery dilatation developed in 42% of the aspirin group versus 15% of the IVIG group.
- Persistent coronary artery dilatation was observed in 14 cases (aspirin) and 3 cases (IVIG) between 30-60 days.
- Coronary arteriography confirmed lesions in 11 of 19 patients in the aspirin group compared to 1 of 6 in the IVIG group.
Conclusions:
- High-dose IVIG in conjunction with aspirin significantly reduces the frequency and persistence of coronary artery abnormalities in patients with Kawasaki disease.
- IVIG is an effective adjunctive therapy for preventing cardiac sequelae in Kawasaki disease.
Abstract:
The ability of high-dose intravenous gammaglobulin (IVGG) to prevent the coronary artery lesion of Kawasaki disease has been studied in a multicentre controlled trial of IVGG plus aspirin versus aspirin alone, aspirin being the conventional treatment for Kawasaki disease. Patients were allocated at random to aspirin (45 cases) or IVGG (40 cases), there being no significant intergroup differences in age, sex ratio, duration of disease until the start of treatment, or severity. The development of coronary artery dilatation was monitored by two-dimensional echocardiography. Within 29 days of the onset of the disease, this lesion had developed in 19 cases (42%) in the aspirin group and in 6 cases (15%) in the IVGG group. There were no new instances of this lesion: in the period 30-60 days coronary artery dilatation persisted in 14 and 3 cases, respectively. In patients found to have echocardiographic abnormalities selective coronary arteriography was done 30-60 days after onset of Kawasaki disease and the lesion was confirmed in 1 of the 6 cases in the IVGG group and in 11 of the 19 controls. High-dose IVGG seems to reduce the frequency of coronary artery abnormalities in patients with Kawasaki disease.